Login to Your Account



Amgen Paying Roche $137.5M For European Neupogen Rights

By Kim Coghill


Thursday, May 9, 2002
Amgen Inc. said it will pay Roche Holding AG $137.5 million to gain control over European assets and business related to two white-cell boosters that are sold in the U.S. under the names Neupogen and Neulasta. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription